台股 » 個股 » 國光生 » 籌碼相關 » 券商分點績效

國光生

(4142)
可現股當沖
  • 股價
    28.10
  • 漲跌
    ▼0.15
  • 漲幅
    -0.53%
  • 成交量
    739
  • 產業
    上市 生技醫療類股
  • 633人加入追蹤

    立即追蹤

  • 本地時間:14:30(已收盤)

     
國光生 (4142)籌碼相關-券商分點績效/獲利分析
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

«前一日     2024/03/26     後一日»

券商獲利排行 - 2024/03/26

券商分點績效總損益(仟)己實現(仟)未實現(仟)買賣超買張賣張均價均買均賣現價
  5.67%36.2036.22424026.626.6028.1
  5.36%34.2-0.134.32324126.626.626.628.1
  5.54%29.5029.52020026.626.6028.1
  5.52%19.1019.11313026.626.6028.1
  5.64%16.5016.51111026.626.6028.1
  5.58%16.4016.41111026.626.6028.1
  5.84%15.5015.51010026.626.6028.1
  5.64%150151010026.626.6028.1
  5.64%150151010026.626.6028.1
  5.64%150151010026.626.6028.1
  5.44%14.5014.51010026.726.7028.1
  5.75%13.7013.789026.626.626.728.1
  5.44%10.2010.277026.626.6028.1
  5.57%8.908.966026.626.6028.1
  5.84%7.807.855026.626.6028.1
  5.84%7.807.855026.626.6028.1
  5.84%7.807.855026.626.6028.1
  5.84%7.807.855026.626.6028.1
  4.09%7.607.657226.626.626.628.1
  5.67%7.507.555026.626.6028.1
  5.64%7.507.555026.626.6028.1
  3.81%6.10.35.846226.726.726.828.1
  5.34%5.705.744026.726.7028.1
  5.24%5.605.644026.726.7028.1
  5.84%4.704.733026.626.6028.1
  5.84%4.704.733026.626.6028.1
  5.84%4.704.733026.626.6028.1
  5.64%4.504.533026.626.6028.1
  5.57%4.504.533026.626.6028.1
  5.51%4.404.433026.626.6028.1
  5.44%4.404.433026.726.7028.1
  5.44%4.404.433026.726.7028.1
  5.44%4.404.433026.726.7028.1
  4.85%3.903.933026.826.8028.1
  4.85%3.903.933026.826.8028.1
  3.19%3.40.4324226.726.626.828.1
  2.97%3.20.2314226.726.626.728.1
  5.84%3.103.122026.626.6028.1
  5.84%3.103.122026.626.6028.1
  5.84%3.103.122026.626.6028.1
  5.84%3.103.122026.626.6028.1
  5.84%3.103.122026.626.6028.1
  5.84%3.103.122026.626.6028.1
  5.84%3.103.122026.626.6028.1
  5.74%3.103.122026.626.6028.1
  5.64%30322026.626.6028.1
  5.64%30322026.626.6028.1
  5.64%30322026.626.6028.1
  5.64%30322026.626.6028.1
  5.64%30322026.626.6028.1

券商虧損排行 - 2024/03/26

券商分點績效總損益(仟)己實現(仟)未實現(仟)買賣超買張賣張均價均買均賣現價
  -5.64%-85.50-85.5-5705726.6026.628.1
  -5.57%-63.80-63.8-4304326.6026.628.1
  -5.10%-59.8-0.7-59.1-4044426.626.826.628.1
  -5.70%-34.90-34.9-2302326.6026.628.1
  -5.64%-300-30-1902026.626.726.628.1
  -5.26%-28.10-28.1-2002026.7026.728.1
  -4.09%-10.90-10.9-731026.626.626.628.1
  -5.11%-10.90-10.9-71826.626.626.628.1
  -4.83%-90-9-61726.626.726.628.1
  -5.84%-7.80-7.8-50526.6026.628.1
  -5.84%-7.80-7.8-50526.6026.628.1
  -4.79%-7.6-0.1-7.5-51626.626.726.628.1
  -5.64%-7.50-7.5-50526.6026.628.1
  -1.47%-7.51.1-8.5-6131926.626.626.728.1
  -5.44%-7.30-7.3-50526.7026.728.1
  -5.84%-6.20-6.2-40426.6026.628.1
  -5.84%-6.20-6.2-40426.6026.628.1
  -5.54%-5.90-5.9-40426.6026.628.1
  -5.24%-5.60-5.6-40426.7026.728.1
  -3.65%-4.8-0.2-4.7-22526.626.626.628.1
  -6.04%-4.80-4.8-30326.5026.528.1
  -5.84%-4.70-4.7-20326.626.926.628.1
  -5.71%-4.60-4.6-30326.6026.628.1
  -5.57%-4.50-4.5-30326.6026.628.1
  -5.44%-4.40-4.4-30326.7026.728.1
  -3.94%-4.20.1-4.3-31426.726.626.728.1
  -2.60%-4.20.2-4.4-33626.626.626.628.1
  -5.84%-3.10-3.1-20226.6026.628.1
  -5.84%-3.10-3.1-20226.6026.628.1
  -5.84%-3.10-3.1-20226.6026.628.1
  -5.84%-3.10-3.1-20226.6026.628.1
  -5.64%-30-3-20226.6026.628.1
  -5.64%-30-3-20226.6026.628.1
  -3.63%-2.90-2.9-11326.726.726.728.1
  -5.44%-2.90-2.9-10226.726.726.728.1
  -5.44%-2.90-2.9-20226.7026.728.1
  -5.44%-2.90-2.9-20226.7026.728.1
  -2.69%-2.90.1-2.9-12426.626.626.628.1
  -5.05%-2.70-2.7-20226.8026.828.1
  -4.85%-2.60-2.6-20226.8026.828.1
  -3.19%-1.7-0.2-1.5-11226.726.826.628.1
  -5.84%-1.60-1.6-10126.6026.628.1
  -5.84%-1.60-1.6-10126.6026.628.1
  -5.84%-1.60-1.6-10126.6026.628.1
  -5.84%-1.60-1.6-10126.6026.628.1
  -5.84%-1.60-1.6-10126.6026.628.1
  -5.84%-1.60-1.6-10126.6026.628.1
  -5.84%-1.60-1.600126.626.726.628.1
  -5.84%-1.60-1.6-10126.6026.628.1
  -5.84%-1.60-1.6-10126.6026.628.1
國光生去年營運轉虧 今年拚重回成長軌道Anue鉅亨-2024/03/13
〈國光生展望〉子公司安特羅腸病毒三期臨床入尾聲 明年展開IPOAnue鉅亨-2023/12/26
〈國光生展望〉流感疫苗申請巴西藥證+破傷風切新市場 外銷業績拚成長Anue鉅亨-2023/12/26
國光生 相關文章